Authors:
Kiran Pulidindi, Kunal Ahuja
Download free PDF
Broccoli Seed Aqueous Extract Market Size & Share 2026-2035
Report ID: GMI13467
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Broccoli Seed Aqueous Extract Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Broccoli Seed Aqueous Extract Market Size
The broccoli seed aqueous extract market was valued at USD 98.8 million in 2025, expected to reach USD 114.6 million in 2026, and is projected to grow at 11.6% CAGR (2026–2035) to reach USD 308.9 million by 2035.
Broccoli Seed Aqueous Extract Market Key Takeaways
Market Leader: CS Health (Caudill Seed) led with over 11.3% market share in 2025.
Leading Players: Top 5 players in this market include CS Health (Caudill Seed), Glanbia Nutritionals, Wellgreen Technology, Bon Natural Life, Xi'an Sonwu Biotech, which collectively held a market share of 43% in 2025.
The broccoli seed aqueous extract market is evolving from a specialty botanical niche into a more specification-led ingredient category. Demand is being shaped by clean-label procurement, greater interest in clinically documented glucoraphanin inputs, and formulators' need for solvent-free extracts that can be used across supplement, food, cosmetic, and pharmaceutical platforms.
GMI Analyst View
Based on input from industry leaders, the broccoli seed aqueous extract market expanded from USD 63.4 million in 2022, driven by increased upstream investment in cGMP-compliant aqueous extraction and growing downstream demand from premium nutraceutical brands prioritizing clean-label glucoraphanin standardization over solvent-derived alternatives.
Broccoli Seed Aqueous Extract Market Trends, Growth Drivers & GMI Forecast Outlook
Clinical substantiation, liquid-format compatibility, and ingredient traceability are reshaping demand for broccoli seed aqueous extract. The outlook depends on whether specialty brands can convert scientific interest into repeat procurement while suppliers meet increasingly exacting requirements for concentration consistency, documentation, and regulatory readiness.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Supplement demand provides the most established commercial foundation for the market because it gives formulators a recurring route to position glucoraphanin around antioxidant, detoxification, and healthy-aging propositions. Aqueous extraction also aligns with buyer preference for ingredient narratives that emphasize solvent-free processing and transparent origin, particularly where premium brands must defend a higher finished-product price.
Functional beverage development broadens the addressable application base beyond capsules and tablets. Water-dispersibility and a more manageable sensory profile can reduce formulation friction in ready-to-drink products, powdered wellness mixes, and fortified plant-based formats, where sulfurous notes and sedimentation can otherwise limit botanical inclusion.
The clinical pipeline is strategically important because it changes the role of documentation from a marketing asset into a procurement requirement. Research on sulforaphane and glucoraphanin continues to give pharmaceutical and clinical-nutrition buyers a clearer rationale for specifying concentration, batch analytics, and evidence packages, although the translation of scientific findings into commercial claims remains selective. [3]Saito, Y. et al. "Sulforaphane as a potential therapeutic agent: a comprehensive analysis of clinical trials and mechanistic insights." jns.cambridge.org
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Branded-ingredient expectations make the market less forgiving for undifferentiated suppliers. A supplier may offer comparable botanical material yet still fail to gain access to higher-value programs if it cannot provide concentration validation, traceability records, or a credible clinical substantiation story. This raises qualification costs and intensifies price pressure in standard-grade supply.
European demand faces a distinct timing challenge. EFSA's updated guidance reinforces the need for compositional, toxicological, and history-of-use evidence when novel food assessment is relevant, which can delay commercialization for new concentration tiers or processing formats. [5]European Food Safety Authority. "Navigating Novel Foods: what EFSA's updated guidance means for safety assessments." efsa.europa.eu Existing supply relationships and well-documented specifications therefore have an advantage over newer market entrants.
Scientific momentum does not eliminate evidentiary uncertainty. The clinical record has expanded, but mixed outcomes, unpublished studies, and population-specific response patterns complicate the conversion of mechanistic credibility into widely accepted health claims. That constraint is especially material for pharmaceutical-grade procurement, where buyers require a higher threshold of documentation before moving from product evaluation to routine sourcing.
GMI Analyst View
We see a two-speed demand structure emerging: supplement and functional food buyers can commercialize differentiated formats relatively quickly, while pharmaceutical demand will advance more selectively as evidence and regulatory pathways mature. This divergence directs supplier value creation toward specifications that combine documentation depth with dependable manufacturing quality.
Broccoli Seed Aqueous Extract Market Segment Analysis
By Glucoraphanin Concentration
Low Concentration (<13% Glucoraphanin)
The low-concentration segment generated USD 14.8 million in 2025 and is projected to grow at 6.1% CAGR (2026–2035). In the broccoli seed aqueous extract market, this tier remains relevant for broad-spectrum greens blends and value-oriented formulations where glucoraphanin is one component in a larger botanical system, but its position is constrained as dosage efficiency becomes more important to supplement developers.
The standard concentration tier generated USD 52.4 million in 2025 and is projected to account for a 47.0% share in 2035. Its commercial durability comes from its fit with established supplement specifications, mid-market price points, and functional-food formulations that require a familiar concentration profile without the added cost or formulation constraints associated with high-tier inputs.
High Concentration (>=20% Glucoraphanin)
The high-concentration tier accounted for a 32.0% share in 2025 and is projected to reach USD 135.9 million by 2035. Demand is supported by applications that need greater active loading within limited capsule fill weights or concentrated food formats, while the technical demands of raw-material selection, extraction control, and analytical validation restrict the number of qualified suppliers.
By Application
Dietary Supplements
Dietary supplements generated USD 57.1 million in 2025 and are projected to represent a 51.6% share in 2035. The segment remains the market's central demand base because standardized glucoraphanin suits capsules, tablets, powders, and combination products, where brands can connect ingredient origin and concentration directly to a condition-specific consumer proposition.
Functional Foods & Beverages
Functional foods & beverages accounted for a 17.4% share in 2025 and are projected to reach USD 65.5 million by 2035. Water-dispersible aqueous extracts are particularly well aligned with ready-to-drink, powdered, and plant-based formats, where formulators need differentiated bioactive ingredients without imposing a strong cruciferous sensory profile on the finished product.
Personal Care & Cosmetics
Personal care & cosmetics generated USD 9.8 million in 2025 and are projected to reach USD 27.5 million by 2035. Skin care is the principal route to demand, as cosmetic formulators seek aqueous botanical actives that can support antioxidant and environmental-stress positioning while simplifying solvent-residue considerations in ingredient qualification.
Pharmaceuticals
Pharmaceutical applications generated USD 8.9 million in 2025 and are projected to reach USD 43.8 million by 2035. This expansion reflects the growing relevance of traceability, purity testing, and batch-specific documentation in clinical-nutrition and pharmaceutical-adjacent programs, although adoption remains dependent on how effectively clinical evidence can support product-development and regulatory strategies.
Animal Nutrition
Animal nutrition accounted for a 5.9% share in 2025 and is projected to grow at 8.2% CAGR (2026–2035). The category benefits from interest in antioxidant and immune-support inputs for livestock and companion-animal products, but lower price tolerance and competition from conventional feed ingredients limit its capacity to match the premiumization seen in human-health applications.
By Grade & Certification
Conventional/Standard Grade
Conventional/standard grade generated USD 59.3 million in 2025 and is projected to hold a 50.0% share in 2035. It remains the broadest-access specification for mass-market supplement, functional-food, and personal-care programs, though its relative position is being challenged as buyers place more value on certification, process documentation, and higher-grade qualification.
Organic Certified
Organic-certified material accounted for a 31.0% share in 2025 and is projected to reach USD 114.3 million by 2035. The grade benefits from procurement alignment with premium brands that use certification as a visible signal of sourcing discipline. U.S. organic product sales reached USD 71.6 billion in 2024 and grew 5.2%, supporting the broader commercial environment for certified ingredient demand. [6]Organic Trade Association. "Growth of U.S. Organic Marketplace Accelerated in 2024." ota.com
Pharmaceutical Grade
Pharmaceutical-grade material generated USD 8.9 million in 2025 and is projected to grow at 15.8% CAGR (2026–2035). Its growth reflects the increasing importance of cGMP manufacturing, identity and purity packages, and lot-level traceability for buyers developing clinical-nutrition, compounding, and pharmaceutical-adjacent formulations.
By Distribution Channel
Supermarkets & Hypermarkets
Supermarkets & hypermarkets generated USD 6.9 million in 2025 and are projected to grow at 13.1% CAGR (2026–2035). Ingredient demand through this channel is created indirectly as mainstream retailers expand shelf space for supplement and functional-food products containing specialty botanicals, encouraging brands to secure scalable and consistently documented supply.
Specialty Stores
Specialty stores accounted for a 15.0% share in 2025 and are projected to reach USD 43.2 million by 2035. Specialist retailers continue to influence early-stage adoption of premium botanical products because knowledgeable staff and category buyers can support consumer education, creating a route for high-concentration and certified formats before they reach wider retail distribution.
Online Retail
Online retail accounted for a 22.0% share in 2025 and is projected to reach USD 92.7 million by 2035. Digital channels favor ingredient-forward brand narratives, allowing supplement companies to communicate sourcing, certification, and concentration details directly to consumers while accelerating feedback loops for reformulation and new-product launches.
Others (Direct B2B, Institutional, MLM)
Other channels, including direct B2B, institutional, and MLM routes, generated USD 55.4 million in 2025 and are projected to account for a 48.0% share in 2035. Direct procurement remains structurally important because ingredient suppliers, contract manufacturers, and finished-product brands often require technical coordination on specifications, quality documentation, and long-term supply arrangements.
GMI Analyst View
We interpret the segment picture as a premiumization cycle with two separate engines: concentration supports dosage-efficient clinical and supplement programs, while certification supports clean-label and brand-trust positioning. Suppliers with a credible portfolio across both requirements should be better insulated from commoditization in standard supply.
Broccoli Seed Aqueous Extract Market Regional Analysis
North America Broccoli Seed Aqueous Extract Market Analysis
North America generated USD 38.0 million in 2025 and is projected to account for a 33.1% share in 2035. The broccoli seed aqueous extract market in the region benefits from established supplement manufacturing, strong demand for branded ingredients, and a research ecosystem that has helped define the commercial relevance of glucoraphanin standardization.
U.S.
The U.S. generated USD 33.5 million in 2025 and is projected to reach USD 90.5 million by 2035. Its position is supported by mature supplement channels, branded-ingredient programs, and demand for organic and cGMP-compliant material that can serve premium nutrition and clinical-use formulations.
Canada
Canada accounted for an 11.8% share of North American revenue in 2025 and is projected to grow at 9.5% CAGR (2026–2035). Demand follows many U.S. supplement and natural-health trends, although regulatory review cycles and a smaller local manufacturing base moderate the pace of market expansion.
Europe Broccoli Seed Aqueous Extract Market Analysis
Europe generated USD 21.7 million in 2025 and is projected to account for a 19.3% share in 2035. The broccoli seed aqueous extract market is supported by sophisticated clean-label supplement and cosmetic buyers, while novel-food compliance requirements can slow the commercialization of new extract formats and concentration profiles.
Germany
Germany generated USD 8.5 million in 2025 and is projected to account for a 38.5% share of European revenue in 2035. Its importance reflects demand from organic supplement and natural-cosmetic manufacturers, as well as durable buyer relationships with established ingredient suppliers.
UK
The UK accounted for a 20.7% share of European revenue in 2025 and is projected to reach USD 12.6 million by 2035. Its functional-food, sports-nutrition, and direct-to-consumer supplement markets create a receptive setting for ingredient differentiation, although suppliers must manage market-specific authorization and compliance requirements.
France
France accounted for a 14.7% share of European revenue in 2025 and is projected to reach USD 8.6 million by 2035. Demand is influenced by the country's cosmetic and nutricosmetic ecosystem, where aqueous botanical ingredients can be incorporated into premium formulations emphasizing sensorial quality and evidence-based positioning.
Asia Pacific Broccoli Seed Aqueous Extract Market Analysis
Asia Pacific generated USD 31.6 million in 2025 and is projected to reach USD 121.3 million by 2035. The broccoli seed aqueous extract market combines a substantial production base with rapidly expanding domestic demand, making the region central to both global supply availability and the market's shift toward higher-concentration formats.
China
China generated USD 21.0 million in 2025 and is projected to reach USD 81.0 million by 2035. Manufacturing clusters, established botanical-extraction capabilities, and expanding domestic nutraceutical demand allow Chinese suppliers to serve export customers while increasing their participation in the regional finished-product market.
Japan
Japan generated USD 7.2 million in 2025 and is projected to account for a 15.7% share of Asia Pacific revenue in 2035. Buyers place considerable value on traceability, analytical documentation, and formulation consistency, particularly in functional-food and beverage programs where supplier qualification requirements are exacting.
South Korea
South Korea accounted for a 1.3% share of Asia Pacific revenue in 2025 and is projected to grow at 17.0% CAGR (2026–2035). The country's skin-care innovation ecosystem creates a differentiated source of demand for cosmetic-grade extracts, especially where antioxidant positioning and rapid product-refresh cycles support ongoing formulation activity.
India
India generated USD 2.8 million in 2025 and is projected to grow at 19.5% CAGR (2026–2035). Growth is supported by domestic supplement manufacturing, increasing incorporation of globally recognized botanicals into local wellness formats, and developing upstream capacity that can improve access to broccoli-seed raw materials and extraction services.
Latin America Broccoli Seed Aqueous Extract Market Analysis
Latin America accounted for a 5.0% share in 2025 and is projected to grow at 10.8% CAGR (2026–2035). The broccoli seed aqueous extract market is developing through local supplement manufacturing and cross-border e-commerce, although price sensitivity continues to favor standard concentration and conventional-grade inputs in much of the region.
Brazil
Brazil accounted for a 51.0% share of Latin American revenue in 2025 and is projected to reach USD 7.2 million by 2035. The country is the region's main demand center, supported by contract manufacturing, growing health-positioned food products, and expanding familiarity with specialty supplement ingredients.
Mexico
Mexico generated USD 1.3 million in 2025 and is projected to account for a 26.4% share of Latin American revenue in 2035. Its supplement manufacturing base and links to North American health-product channels create a practical entry route for suppliers that can satisfy local registration and procurement requirements.
Middle East & Africa Broccoli Seed Aqueous Extract Market Analysis
Middle East & Africa generated USD 2.6 million in 2025 and is projected to grow at 16.0% CAGR (2026–2035). The broccoli seed aqueous extract market is small but gaining commercial relevance as premium supplement retail expands in Gulf markets and established manufacturing and distribution hubs provide access to a wider regional customer base.
South Africa
South Africa accounted for a 19.2% share of Middle East & Africa revenue in 2025 and is projected to grow at 15.0% CAGR (2026–2035). Its contract-manufacturing and pharmacy-led health-product infrastructure make it a practical regional entry point for international suppliers seeking qualified distribution and formulation partners.
Saudi Arabia
Saudi Arabia generated USD 0.7 million in 2025 and is projected to reach USD 3.2 million by 2035. Demand is linked to expanding premium supplement retail, increasing health awareness among urban consumers, and the need for locally distributed ingredients that meet quality and traceability expectations.
UAE
The UAE accounted for a 30.8% share of Middle East & Africa revenue in 2025 and is projected to reach USD 3.7 million by 2035. Its role as a re-export and distribution center magnifies demand beyond domestic use, while Halal requirements and proximity to South Asian supply routes influence supplier selection.
GMI Analyst View
We expect Asia Pacific to exert increasing influence over both the supply economics and demand composition of the market. China's manufacturing depth, India's expanding formulation base, and South Korea's cosmetics-led demand create distinct growth pathways, while North America retains strategic importance for branded and evidence-led procurement.
Broccoli Seed Aqueous Extract Market Share & Competitive Landscape
The broccoli seed aqueous extract market share structure is moderately concentrated at the ingredient-supplier level, with the five leading producers collectively accounting for approximately 43% of global revenue in 2025. Competition is shaped less by scale alone than by the ability to provide consistent glucoraphanin specifications, credible analytical documentation, certification breadth, and supply-chain reliability.
CS Health (Caudill Seed) held an 11.3% revenue share in 2025. Its BroccoPhane platform and association with glucoraphanin research give the company a differentiated position in branded, clinically oriented ingredient programs, where downstream customers value origin transparency and substantiation as much as active concentration.
Glanbia Nutritionals held a 9.6% market share in 2025. Its broader nutrition-ingredient portfolio and established formulator relationships provide cross-selling opportunities across supplements, sports nutrition, and functional-food development, allowing broccoli seed extract to be positioned within wider product-development solutions.
Wellgreen Technology held an 8.4% market share in 2025. The company competes through manufacturing scale across standard and high-concentration material and through certification capability, which enables it to address both cost-sensitive supplement customers and premium clean-label buyers.
Bon Natural Life Limited and Xi'an Sonwu Biotech Co., Ltd. remain relevant participants in export-oriented supply, particularly where buyers prioritize concentration range, price competitiveness, and analytical documentation. Across the broader supplier base, Chinese extract manufacturers, regional producers, and toll-manufacturing specialists compete for standard and mid-tier contracts, while pharmaceutical-grade and dual-certified capacity presents a more defensible route to differentiation.
Recent Industry Developments
BioVivo Science announced a U.S.-grown broccoli seed extract launch in October 2025, positioning domestic sourcing as a response to traceability, tariff, and lead-time concerns for imported botanical ingredients. The company identified its Jeffersonville, Indiana, cGMP-certified extraction facility as the production platform supporting the launch. [7]BioVivo Science. "BioVivo Science Expands Its U.S. Botanical Portfolio with New Broccoli Seed, Saw Palmetto, and Cranberry Extracts." biovivoscience.com
A randomized, placebo-controlled study published in *Nature Microbiology* in February 2025 examined broccoli sprout aqueous extract in adults with prediabetes and identified a microbiota-stratified subgroup with enhanced metabolic response. The finding adds to the scientific basis for precision-nutrition approaches, while underscoring that clinical response may not be uniform across target populations. [4]Dwibedi, C. et al. "Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial." nature.com
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →